Effective multiple sclerosis management through improved patient assessment

Journal of Neuroscience Nursing

Volumn 40, Issue 3, 2008, Pages 150-157

  Ross, Amy Perrin ^a   Hackbarth, Natalie ^b   Rohl, Christine ^c   Whitmyre, Kristi ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b EMD Serono Inc ^*

^c EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; IMMUNOLOGIC FACTOR; MITOXANTRONE; PEPTIDE;

DAILY LIFE ACTIVITY; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; HUMAN; MULTIPLE SCLEROSIS; NEEDS ASSESSMENT; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHYSIOTHERAPY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SELF CARE; SELF EVALUATION;

ACTIVITIES OF DAILY LIVING; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS; NEEDS ASSESSMENT; NURSING ASSESSMENT; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PEPTIDES; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; QUESTIONNAIRES; SELF ASSESSMENT (PSYCHOLOGY); SELF CARE;

EID: 49849103996     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/01376517-200806000-00005     Document Type: Article

References (48)

1. Alpini, D., Pugnetti, L., Caputo, D., Cornelio, F., Capobianco, S., & Cesarani, I. (2004). Vestibular evoked myogenic potential in multiple sclerosis: Clinical and imaging correlations. Multiple Sclerosis, 10 (3), 316-321. (Pubitemid 38807461)
2. Bamer, A. M., Cetin, K., Amtmann, D., Bowen, J. D., & Johnson, K. L. (2007). Comparing a self report questionnaire with physician assessment for determining multiple sclerosis clinical disease course: A validation study. Multiple Sclerosis, 13 (8), 1033-1037 (Epub). (Pubitemid 351541439)
3. Beck, R. W., Cleary, P. A., Anderson, M. M., Jr., Keltner, J. L., Shults, W. T., Kaufman, D. I., et al. (1992). A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. New England Journal of Medicine, 326 (9), 581-588.
4. Berlex, Inc. (2006). Betaseron [Package insert]. Retrieved February 17, 2006, from www.berlex. com/html/products/pi/Betaseron-PI. pdf.
5. Betts, C. D., Jones, S. J., Fowler, C. G., & Fowler, C. J. (1994). Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain, 117 (Pt. 6), 1303-1310.
6. Bever, C. T., Jr., Anderson, P. A., Leslie, J., Panitch, H. S., Dhib-Jalbut, S., Khan, O. A., et al. (1996). Treatment with oral 3, 4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology, 47 (6), 1457-1462. (Pubitemid 26422536)
7. Biogen Idec, Inc. (2004). Tysabri [Package insert]. Cambridge, MA: Author.
8. Biogen Idec, Inc. (2006). Avonex [Package insert]. Retrieved February 17, 2006, from www.avonex. com/msavProject/avonex. portal/-baseurl/threeColLayout/ SCSRepository/en-US/avonex/includes/footer/prescribe-info-med-guide. xml.
9. Brown, S. A. (2000). Swallowing and speaking: Challenges for the MS patient. International Journal of MS Care, 2, 2.
10. Charil, A., Zijdenbos, A. P., Taylor, J., Boelman, C., Worsley, K. J., Evans, A. C., et al. (2003). Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: Application to 452 patient data sets. NeuroImage, 19 (3), 532-544. (Pubitemid 36918200)
11. Cohen, R. A., & Fisher, M. (1989). Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology, 46 (6), 676-680. (Pubitemid 19150949)
12. Compston, A., & Coles, A. (2002). Multiple sclerosis. Lancet, 359 (9313), 1221-1231. (Pubitemid 34304266)
13. Dierich, M. (2000). Bladder dysfunction. In J. Burks & K. Johnson (Eds.), Multiple sclerosis: Diagnosis, medical management, and rehabilitation (pp. 433-451). New York: Demos Vermande.
14. Elan Pharmaceuticals. (2002). Zanaflex [Package insert]. Dublin, Ireland: Author.
15. EMD Serono, Inc. (2006). Novantrone [Package insert]. Retrieved April 4, 2008, from www.novantrone. com/assets/pdf/novantrone-prescribing-info. pdf.
16. Goodwin, R. J., & Fowler, C. J. (1997). Bladder, bowel and sexual dysfunction: Recent advances. In A. Thompson, C. Polman, & R. Hohlfeld (Eds.), Multiple sclerosis: Clinical challenges and controversies (pp. 265-281). London: Martin Dunitz.
17. Greene, Y. M., Tariot, P. N., Wishart, H., Cox, C., Holt, C. J., Schwid, S., et al. (2000). A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. Journal of Clinical Psychopharmacology, 20 (3), 350-356. (Pubitemid 30318365)
18. Hawker, K. S., & Frohman, E. M. (2001). Bladder, bowel, and sexual dysfunction in multiple sclerosis. Current Treatment Options in Neurology, 3 (3), 207-214.
19. Heckman-Stone, C., & Stone, C. (2001). Pain management techniques used by patients with multiple sclerosis. Journal of Pain: Official Journal of the American Pain Society, 2 (4), 205-208.
20. Keegan, B. M., & Noseworthy, J. H. (2002). Multiple sclerosis. Annual Review of Medicine, 53, 285-302. (Pubitemid 34182821)
21. Kessler, R. C., & Ustun, T. B. (2004). The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). International Journal of Methods in Psychiatric Research, 13 (2), 93-121.
22. Krupp, L. B., Elkins, L. E., Scheffer, R. S., Smiroldo, J., & Coyle, P. K. (1999). Donepezil for the treatment of memory impairment in MS [abstract]. Neurology, 52, A137.
23. Krupp, L. B., & Rizvi, S. A. (2002). Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology, 58 (8; Suppl. 4), S32-S39. (Pubitemid 34411851)
24. Lisak, D. (2001). Overview of symptomatic management of multiple sclerosis. Journal of Neuroscience Nursing, 33 (5), 224-230.
25. Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology, 46 (4), 907-911. (Pubitemid 26134623)
26. Multiple Sclerosis Council for Clinical Practice Guidelines. (1998). Fatigue and multiple sclerosis (pp. 1-27). Washington, DC: Paralyzed Veterans of America.
27. National Multiple Sclerosis Society. (n. d.). Healthy living with MS: MS and pain. Retrieved May 18, 2007, from www.nationalmssociety.org/site/ PageServer?pagename=HOM-LIVE-spotlight-pain.
28. National Multiple Sclerosis Society. (2006a). MS the disease. Retrieved April 4, 2008, from www.nationalmssociety.org/pressroom/ms-the-disease/index. aspx.
29. National Multiple Sclerosis Society. (2006b). Sourcebook: Heat/temperature sensitivity. Retrieved April 4, 2008, from www.nationalms society.org/about-multiple-sclerosis/treatments/exacerbations/heat temperature-sensitivity/index. aspx.
30. Ortho-McNeil Pharmaceutical, Inc. (2004). Ditropan [Package insert]. Raritan, NJ: Author.
31. Panitch, H., Thisted, R. A., Pope, L. E., & Berg, J. E. (2005). A doubleblind, placebo-controlled, multicenter study to assess the safety and efficacy of AVP-923 (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with multiple sclerosis [Abstract]. Neurology, 64 (Suppl. 1), A392.
32. Pfizer, Inc. (2006). Rebif [Package insert]. Retrieved February 17, 2006, from http://professional. rebif. com/assets/pdfs/rebif-prescribing-info. pdf.
33. Pharmacia & Upjohn Company. (2004). Detrol [Package insert]. New York: Author.
34. Procter & Gamble Pharmaceuticals. (2002). Dantrolene [Package insert]. Cincinnati, OH: Author.
35. Rammohan, K. W., Rosenberg, J. H., Lynn, D. J., Blumenfeld, A. M., Pollak, C. P., & Nagaraja, H. N. (2002). Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. Journal of Neurology, Neurosurgery, and Psychiatry, 72 (2), 179-183. (Pubitemid 34102149)
36. Roche Products. (2001). Valium [Package insert]. Basel, Switzerland: Author.
37. Runmarker, B., & Andersen, O. (1993). Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain, 116 (Pt. 1), 117-134. (Pubitemid 23087038)
38. Schapiro, R. T. (1994). Symptom management in multiple sclerosis. Annals of Neurology, 36 (Suppl.), S123-S129.
39. Schapiro, R. T. (1998a). Bladder symptoms. In Symptom management in multiple sclerosis (3rd ed., pp. 67-81). New York: Demos.
40. Schapiro, R. T. (1998b). Sexuality. In Symptom management in multiple sclerosis (3rd ed., pp. 59-65). New York: Demos.
41. Schapiro, R. T. (2001). Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. Current Neurology and Neuroscience Reports, 1 (3), 299-302.
42. Schapiro, R. T. (2002). Pharmacologic options for the management of multiple sclerosis symptoms. Neurorehabilitation and Neural Repair, 16 (3), 223-231. (Pubitemid 34984897)
43. Schiffer, R. B., Herndon, R. M., & Rudick, R. A. (1985). Treatment of pathologic laughing and weeping with amitriptyline. New England Journal of Medicine, 312 (23), 1480-1482.
44. Schwarz Pharma. (2003). Kemstro [Package insert]. Monheim, Germany: Author.
45. Silverman, F. H. (1997). Augmentative communication. In Computer applications for augmenting the management of speech, language, and hearing disorders (pp. 83-99). Needham Heights, MA: Allyn and Bacon.
46. Teva Neuroscience, Inc. (2006). Copaxone [Package insert]. Retrieved April 4, 2008, from www.copaxone. com/pdf/PrescribingInformation. pdf.
47. Weinshenker, B. G., Bass, B., Rice, G. P., Noseworthy, J., Carriere, W., Baskerville, J., et al. (1989). The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain, 112 (Pt. 1), 133-146. (Pubitemid 19056478)
48. White, A. T., Wilson, T. E., & Petajan, J. H. (1997). Effect of preexercise cooling on physical function and fatigue in multiple sclerosis patients. Medicine and Science in Sports and Exercise, 29 (Suppl. 5), S83.